And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, escort Mrs. Pharmalot to a musical event, and promenade with the official mascot. We also plan to hold another listening party, where the rotation will likely include this, this, this, this and this. And what about you? As noted previously, this remains a fine time to enjoy the great outdoors — perhaps a drive in the country is in order or a long walk by a lake or ocean. If the weather fails to cooperate, you could take in a moving picture show. Or maybe this is an opportunity to boost your local economy with a holiday purchase. Speaking of holidays, we will be off next week but never fear, a team of pinch hitters will be on hand. Meanwhile, whatever you do over the next 10 days or so, we hope you do something…
STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
In short
Several leading pharmaceutical companies have cut early-stage drug development timelines by up to half this year by applying artificial intelligence to advanced research tasks. Scientific leaders at major drugmakers report using the technology to design molecules, select viable candidates, and detect safety issues before entering clinical phases. Meanwhile, major pharmaceutical manufacturers have pledged to a Congressional committee that they will avoid establishing new clinical trials in China's Xinjiang region or at military-connected medical facilities. This decision follows congressional inquiries regarding intellectual property risks and ethical standards at sensitive overseas trial lo…
Key points
- Global pharmaceutical companies are successfully deploying artificial intelligence to sol…: Global pharmaceutical companies are successfully deploying artificial intelligence to solve complex scientific challenges beyond mere administrative filings.
- Scrutiny from the House Select Committee on China is directly influencing where multinati…: Scrutiny from the House Select Committee on China is directly influencing where multinational drug companies establish clinical trials.
- Concerns regarding intellectual property risks and military ties are actively shaping pha…: Concerns regarding intellectual property risks and military ties are actively shaping pharmaceutical research strategies in sensitive foreign regions.